Monaco Asset Management SAM Has $5.79 Million Holdings in QuidelOrtho Corporation $QDEL

Monaco Asset Management SAM raised its holdings in QuidelOrtho Corporation (NASDAQ:QDEL) by 131.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 202,595 shares of the company’s stock after acquiring an additional 114,895 shares during the quarter. QuidelOrtho accounts for 1.0% of Monaco Asset Management SAM’s investment portfolio, making the stock its 23rd biggest holding. Monaco Asset Management SAM’s holdings in QuidelOrtho were worth $5,786,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Global Retirement Partners LLC lifted its stake in QuidelOrtho by 3,691.7% in the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock valued at $26,000 after buying an additional 886 shares during the period. Camelot Portfolios LLC acquired a new position in QuidelOrtho in the fourth quarter valued at approximately $29,000. Hantz Financial Services Inc. lifted its stake in QuidelOrtho by 50.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock valued at $31,000 after buying an additional 362 shares during the period. Larson Financial Group LLC lifted its stake in QuidelOrtho by 322.2% in the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock valued at $39,000 after buying an additional 1,015 shares during the period. Finally, Aster Capital Management DIFC Ltd acquired a new position in QuidelOrtho in the third quarter valued at approximately $63,000. 99.00% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on QDEL. UBS Group reissued a “neutral” rating and issued a $12.00 price target on shares of QuidelOrtho in a research note on Thursday, May 7th. Zacks Research lowered QuidelOrtho from a “hold” rating to a “strong sell” rating in a research report on Tuesday, February 17th. Citigroup lowered their target price on QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Jefferies Financial Group lowered QuidelOrtho from a “buy” rating to a “hold” rating and lowered their target price for the stock from $35.00 to $12.50 in a research report on Thursday, May 7th. Finally, Wall Street Zen lowered QuidelOrtho from a “buy” rating to a “hold” rating in a research report on Sunday, April 12th. Three investment analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, QuidelOrtho currently has a consensus rating of “Reduce” and an average price target of $14.88.

QuidelOrtho Price Performance

Shares of NASDAQ:QDEL opened at $13.02 on Monday. The company has a quick ratio of 0.80, a current ratio of 1.43 and a debt-to-equity ratio of 1.33. QuidelOrtho Corporation has a twelve month low of $9.92 and a twelve month high of $35.58. The stock’s 50 day moving average is $13.41 and its 200-day moving average is $21.84. The firm has a market capitalization of $887.83 million, a price-to-earnings ratio of -0.73 and a beta of 0.77.

QuidelOrtho (NASDAQ:QDEL) last issued its earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The firm had revenue of $619.80 million for the quarter, compared to analyst estimates of $665.23 million. During the same period in the previous year, the company earned $0.74 earnings per share. QuidelOrtho’s revenue for the quarter was down 10.5% compared to the same quarter last year. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Sell-side analysts forecast that QuidelOrtho Corporation will post 1.83 EPS for the current fiscal year.

QuidelOrtho Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.